Last reviewed · How we verify
BE-PEP Rifampicin
BE-PEP Rifampicin is a rifampicin-based formulation designed to improve bioavailability and reduce dosing frequency for tuberculosis treatment.
BE-PEP Rifampicin is a rifampicin-based formulation designed to improve bioavailability and reduce dosing frequency for tuberculosis treatment. Used for Tuberculosis (pulmonary and extrapulmonary).
At a glance
| Generic name | BE-PEP Rifampicin |
|---|---|
| Sponsor | Institute of Tropical Medicine, Belgium |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase (mycobacterial) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Rifampicin is a well-established bacterial RNA polymerase inhibitor that disrupts mycobacterial transcription. BE-PEP (Bioavailability Enhancement Peptide) technology is applied to rifampicin to enhance its oral absorption and pharmacokinetic properties, potentially allowing for improved efficacy and simplified dosing regimens in tuberculosis therapy.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
Common side effects
- Hepatotoxicity
- Gastrointestinal disturbance
- Rash
- Drug-drug interactions
Key clinical trials
- Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar (PHASE3)
- Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) (PHASE2)
- Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |